Post by Brandon Capital

Australia’s $250bn biotech sector is our largest manufactured export industry, built on decades of patient capital. It takes up to 18 years to get a life-saving treatment to market, and 93% of candidates fail along the way. But proposed changes to Capital Gains Tax (CGT) and the R&D Tax Incentive (RDTI) threaten to fundamentally disrupt this delicate ecosystem. Testifying before the Senate hearing on Tuesday, Brandon Capital Co-Founder and CEO, Dr. Chris Nave, warned that the current proposals alter the sector’s risk-versus-reward profile entirely. By hitting biotech with a structural double whammy, these changes risk forcing vital venture capital and home-grown clinical intellectual property to flee offshore — right when companies reach their most capital-intensive growth phases. The government’s decision to open a consultation period is a positive step, but we need concrete, permanent actions such as a clear biotech CGT carve-out and realistic R&D timelines, to ensure Australia remains globally competitive. Read the perspective from our Chair, Peter Beattie, featured today on the front page of The Australian, on why protecting this sector is a matter of absolute national interest: https://lnkd.in/gy8JQfjf  [𝘗𝘭𝘦𝘢𝘴𝘦 𝘯𝘰𝘵𝘦: 𝘧𝘶𝘭𝘭 𝘢𝘳𝘵𝘪𝘤𝘭𝘦 𝘣𝘦𝘩𝘪𝘯𝘥 𝘢 𝘱𝘢𝘺𝘸𝘢𝘭𝘭] #Biotech #VentureCapital #Innovation #CGT